NEW YORK, April 20, 2020 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and ...
Statistical classifications generally follow relevant policy and societal trends. There are therefore opportunities to add statistical codes for bio-based products and materials to statistical ...
The environmental problems caused by adverse effects of plastics and other materials has increased interest for bio-based materials. In this context, projects such as the EU funded BioMonitor set out ...
* MUSTANG BIO RECEIVES ADVANCED THERAPY MEDICINAL PRODUCT CLASSIFICATION FROM EUROPEAN MEDICINES AGENCY FOR MB-107 LENTIVIRAL GENE THERAPY FOR X-LINKED SEVERE COMBINED IMMUNODEFICIENCY Source text for ...
The FDA has issued new risk classification orders for two series of products, including in vitro diagnostics for hepatitis C, two of which the agency down-regulated from class III to class II. However ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results